1 active not recruiting. .
Follow Lixiaoling: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors Trastuzumab Rezetecan, Other Drugs - Recurrent or Metastatic Solid Tumors | Active not recruiting | Lixiaoling | 30 | 2025-07-10 | 2026-02-04 |
Recurrence (1)
China (1)